These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 38362379)

  • 1. Efficacy and safety of raltitrexed-eluting CalliSpheres
    Sun Z; Jiao D; Fang Y; Liu Y; Xu K; Zhang C; Huang Y; Han X
    Ther Adv Med Oncol; 2024; 16():17588359241229661. PubMed ID: 38362379
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical outcomes of doxorubicin-eluting CalliSpheres® beads-transarterial chemoembolization for unresectable or recurrent esophageal carcinoma.
    Bi Y; Shi X; Ren J; Yi M; Han X; Song M
    BMC Gastroenterol; 2021 May; 21(1):231. PubMed ID: 34020608
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pirarubicin-loaded CalliSpheres® drug-eluting beads for the treatment of patients with stage III-IV lung cancer.
    Bi Y; Shi X; Yi M; Han X; Ren J
    Acta Radiol; 2022 Mar; 63(3):311-318. PubMed ID: 33615822
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preliminary outcomes of raltitrexed eluting bead-transarterial chemoembolization using Callispheres® beads for gastrointestinal adenocarcinoma liver metastasis.
    Bi Y; Jiao D; Wang Y; Han X; Ren J
    World J Surg Oncol; 2022 Jul; 20(1):229. PubMed ID: 35821043
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical Outcomes of Drug-Eluting Bead Transarterial Chemoembolization Loaded with Raltitrexed for the Treatment of Unresectable or Recurrent Hepatocellular Carcinoma.
    Bi Y; Jiao D; Ren J; Han X
    Can J Gastroenterol Hepatol; 2022; 2022():2602121. PubMed ID: 36051250
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Transarterial chemoembolization of unresectable renal cell carcinoma with doxorubicin-loaded CalliSpheres drug-eluting beads.
    Bi Y; Shi X; Ren J; Yi M; Han X
    Sci Rep; 2022 May; 12(1):8136. PubMed ID: 35581365
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy, safety, and prognostic factors of drug-eluting beads transarterial chemoembolization using CalliSpheres in treating huge hepatocellular carcinoma patients.
    Wang Z; Mu K; Lv Y; Zhao L; Li B; Hao Y; Wang N
    Ir J Med Sci; 2022 Dec; 191(6):2493-2499. PubMed ID: 35064533
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oxaliplatin Eluting CalliSpheres Microspheres for the Treatment of Unresectable or Recurrent Hepatocellular Carcinoma.
    Bi Y; Ren K; Ren J; Ma J; Han X
    Front Pharmacol; 2022; 13():923585. PubMed ID: 36034827
    [No Abstract]   [Full Text] [Related]  

  • 9. Comprehensive predictive factors for CalliSpheres® microspheres (CSM) drug-eluting bead-transarterial chemoembolization and conventional transarterial chemoembolization on treatment response and survival in hepatocellular carcinoma patients.
    Chen C; Qiu H; Yao Y; Zhang Z; Ma C; Ma Y; Zhao C; Xiang H; Zhao H; Zheng C; Xiong B; Li H; Long Q; Zhou J; Luo C; Hu H
    Clin Res Hepatol Gastroenterol; 2021 Mar; 45(2):101460. PubMed ID: 32593695
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CalliSpheres drug-eluting beads versus lipiodol transarterial chemoembolization in the treatment of hepatocellular carcinoma: a short-term efficacy and safety study.
    Wu B; Zhou J; Ling G; Zhu D; Long Q
    World J Surg Oncol; 2018 Mar; 16(1):69. PubMed ID: 29587773
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The second-line treatment of hepatocellular carcinoma with CalliSpheres drug-eluting bead transarterial chemoembolization combined with regorafenib: A safety and efficacy analysis.
    Liu S; Liu C; Wang Q; Liu Y; Wang D; Zhao G; Yu G
    Ir J Med Sci; 2024 Jun; 193(3):1215-1222. PubMed ID: 38300460
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preliminary outcomes of DEB-TACE loaded with raltitrexed in the treatment of unresectable or recurrent hepatocellular carcinoma.
    Bi Y; Wang Y; Zhang W; Lu H; Ren J; Han X
    Cancer Imaging; 2023 Feb; 23(1):19. PubMed ID: 36814327
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Short-term efficacy and safety of callispheres drug-loaded microsphere embolization in primary hepatocellular carcinoma.
    Li J; Wang N; Shi C; Liu Q; Song J; Ye X
    J Cancer Res Ther; 2021 Jul; 17(3):733-739. PubMed ID: 34269307
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and Safety of Drug-Eluting Beads Transarterial Chemoembolization by CalliSpheres
    Sun J; Zhou G; Xie X; Gu W; Huang J; Zhu D; Hu W; Hou Q; Shi C; Li T; Zhang X; Ji W; Ying S; Peng Z; Zhou J; Yu Z; Ji J; Du H; Guo X; Fang J; Han J; Xu H; Sun Z; Yu W; Shao G; Wu X; Hu H; Li L; Zheng J; Luo J; Chen Y; Cao G; Hu T
    Oncol Res; 2020 Feb; 28(1):75-94. PubMed ID: 31558180
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of Treatment Response, Survival Profiles, as Well as Safety Profiles Between CalliSpheres
    Duan X; Liu J; Han X; Ren J; Li H; Li F; Ju S
    Front Oncol; 2021; 11():793581. PubMed ID: 35127501
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Propensity score matching analysis of efficacy of drug-eluting beads (DEB)-TACE loaded with different drugs in the treatment of hepatocellular carcinoma.
    Yang L; Wang H; Li S; Gan G; Deng W; Chang Y; Zhang L
    Am J Transl Res; 2023; 15(2):1526-1532. PubMed ID: 36915718
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of treatment efficacy and safety between drug-eluting bead transarterial chemoembolization with CalliSpheres
    Ma Y; Zhao C; Zhao H; Li H; Chen C; Xiang H; Zheng C; Ma C; Luo C; Qiu H; Yao Y; Hu H; Xiong B; Zhou J; Zhu H; Long Q
    Am J Transl Res; 2019; 11(12):7456-7470. PubMed ID: 31934293
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The safety and efficacy of oxaliplatin-loaded drug-eluting beads transarterial chemoembolization for the treatment of unresectable or advanced lung cancer.
    Bi Y; Li F; Ren J; Han X
    Front Pharmacol; 2022; 13():1079707. PubMed ID: 36518678
    [No Abstract]   [Full Text] [Related]  

  • 19. An investigation of efficacy, safety, and prognostic factors of drug-eluting beads-transarterial chemoembolization operation with CalliSpheres
    Zhang X; Lin X; Qiu H; Peng Z
    J Clin Lab Anal; 2019 Oct; 33(8):e22975. PubMed ID: 31328832
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sorafenib or placebo plus TACE with doxorubicin-eluting beads for intermediate stage HCC: The SPACE trial.
    Lencioni R; Llovet JM; Han G; Tak WY; Yang J; Guglielmi A; Paik SW; Reig M; Kim DY; Chau GY; Luca A; Del Arbol LR; Leberre MA; Niu W; Nicholson K; Meinhardt G; Bruix J
    J Hepatol; 2016 May; 64(5):1090-1098. PubMed ID: 26809111
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.